The epidermal growth factor receptor (EGFR) is closely
associated
with tumor development and progression and thus an important target
structure for imaging and therapy of various tumors. As a result of
its important role in malignancies of various origins and the fact
that antibody-based compounds targeting the EGFR have significant
drawbacks in terms of
in vivo
pharmacokinetics, several
attempts have been made within the last five years to develop peptide-based
EGFR-specific radioligands based on the GE11 scaffold. However, none
of these approaches have shown convincing results so far, which has
been proposed to be attributed to different potential challenges associated
with the GE11 lead structure: first, an aggregation of radiolabeled
peptides, which might prevent their interaction with their target
receptor, or second, a relatively low affinity of monomeric GE11,
necessitating its conversion into a multimeric or polymeric form to
achieve adequate EGFR-targeting properties. In the present work, we
investigated if these aforementioned points are indeed critical and
if the EGFR-targeting ability of GE11 can be improved by choosing
an appropriate hydrophilic molecular design or a peptide multimer
system to obtain a promising radiopeptide for the visualization of
EGFR-overexpressing malignancies by positron emission tomography (PET).
For this purpose, we developed several monovalent
68
Ga-labeled
GE11-based agents, a peptide homodimer and a homotetramer to overcome
the challenges associated with GE11. The developed ligands were successfully
labeled with
68
Ga
3+
in high radiochemical yields
of ≥97% and molar activities of 41–104 GBq/μmol.
The resulting radiotracers presented log
D
(7.4)
values between −2.17 ± 0.21 and −3.79 ±
0.04 as well as a good stability in human serum with serum half-lives
of 112 to 217 min for the monovalent radiopeptides and 84 and 62 min
for the GE11 homodimer and homotetramer, respectively. In the following
in vitro
studies, none of the
68
Ga-labeled radiopeptides
demonstrated a considerable EGF receptor-specific uptake in EGFR-positive
A431 cells. Moreover, none of the agents was able to displace [
125
I]I-EGF from the EGFR in competitive displacement assays
in the same cell line in concentrations of up to 1 mM, whereas the
endogenous receptor ligand hEGF demonstrated a high affinity of 15.2
± 3.3 nM. These results indicate that it is not the aggregation
of the GE11 sequence that seems to be the factor limiting the usefulness
of the peptide as basis for radiotracer design but the limited affinity
of monovalent and small homomultivalent GE11-based radiotracers to
the EGFR. This highlights that the development of small-molecule GE11-based
radioligands is not promising.